Answers are grounded in this paper and cite their sources.
Case report reveals complexities in diagnosing IgM multiple myeloma, suggesting distinct management for plasma cell disorders.
IgM monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma cell proliferative disorder associated with the secretion of an IgM monoclonal protein. Unlike IgG or IgA MGUS, which are associated with progression to multiple myeloma (MM), IgM MGUS is primarily associated with the risk of progression to Waldenström macroglobulinemia (WM), also referred to in pathologic reports as lymphoplasmacytic lymphoma. In rare instances, IgM MGUS can progress to MM with classic clinical features of osteolytic lesions, unlike WM, which presents similar to a low-grade lymphoma. IgM multiple myeloma (IgM-MM) and WM share the finding of an IgM monoclonal protein but are distinct malignancies with differing clinical presentations, prognosis, and treatment approaches, and distinguishing between these disorders is critical for appropriate management. IgM MM is a rare disorder that accounts for 0.5%–1% of all myeloma cases; thus, data are limited [1, 2]. We have defined IgM-MM as a symptomatic clonal plasma cell proliferative disorder characterized by an IgM monoclonal protein (regardless of size), 10% or more clonal cells on bone marrow biopsy, plus the presence of lytic bone lesions and/or translocation t(11;14) [3]. The presence of t(11;14) is included as an additional distinguishing feature to differentiate IgM-MM and WM because the latter is a malignancy of lymphoid/plasma cells that have not yet undergone class switching, and the t(11;14) translocation in MM occurs in the switch regions in plasma cells involved in the process of class switching. The strict disease definition of IgM-MM is meant to clearly differentiate a set of patients who have a prognosis and treatment requirement similar to MM, rather than WM. Other biomarkers such as plasma cell morphology or lack of CD20 expression do not reliably produce an MM phenotype, and data are limited to consider them in the disease definition [3]. Two small studies by King et al. and Avet-Loiseau and colleagues showed cyclin D1 overexpression or t(11;14) is present in most IgM MM patients [4, 5]. However, the largest retrospective series of 134 IgM MM cases, studied by Castillo et al., found t(11;14) in only 40% of cases [6]. While a strict disease definition of IgM-MM requiring osteolytic lesions or t(11;14) helps to differentiate it from WM, it can also inadvertently exclude patients with less advanced disease, especially those with other MM-associated cytogenetic abnormalities and thus lead to missed diagnosis in patients who may need MM-like therapy but do not meet the above-mentioned criteria. We describe the case of a 54-year-old man who presented with a three-year history of severe anemia and kappa light chain restricted paraproteinemia. At initial presentation, he had a markedly elevated IgM of 2558 mg/dL. Previous attempts to confirm the etiology of the anemia had yielded no result, with normal esophagoduodenoscopy and colonoscopy as well as a failed bone marrow biopsy attempt. The patient was managed with intermittent transfusions for two years before he presented to our center. He was found to have jejunal bleeding, which was promptly treated with epinephrine and hemostatic clipping. Despite this treatment, anemia persisted with a hemoglobin of 6.4 g/dL. At this point, he was referred to hematology and was found to have an M spike of 1.7 g/dL, beta-2 microglobulin 2.77 mg/L, kappa free light chain 95.95 mg/dL, lambda free light chain 0.8 mg/dL, and K/L ratio of 119.94. A 24-h urine protein electrophoresis revealed a 169.5 mg/24-h M spike. A CT skeletal survey showed no lytic lesions. Bone marrow biopsy showed greater than 60% plasma cells, and FISH revealed t(14;20) translocation. There was no evidence of amyloid deposition on Congo red staining. This case is relevant for several reasons. First, although the patient does not meet the strict criteria for IgM-MM, there is the presence of an MM associated immunoglobulin heavy chain translocation, t(14;20). Similar to t(11;14), the t(14;20) translocation is also one that occurs in the switch region when plasma cells are in the process of undergoing switch recombination. Most such cells secrete IgG or IgA but, depending on the timing of the event, may occur in a cell where the heavy chain switch is in the preparatory phase but has not yet occurred, and hence the cell is still secreting IgM. Based on the presence of the t(14;20) translocation, which is not seen in WM, we would consider this patient as having IgM-MM. To the best of our knowledge, this is the first reported case of immunoglobulin M multiple myeloma with t(14;20). Our understanding of the biology of t(14;20) is that it is a high-risk MM finding associated with a higher prevalence of renal dysfunction and lytic lesions at diagnosis [7]. Second, accurate distinction between IgM-MM and WM in this patient has major consequences for the treatment chosen. Finally, based on this, we can consider extending the definition of IgM-MM to beyond t(11;14) and t(14;20) translocations, to the three other common MM associated immunoglobulin heavy chain translocations, namely, t(4;14), t(6;14), and t(14;16), when they occur in the context of an IgM secreting malignancy. The case report was conducted under a retrospective study of plasma cell disorders approved by the Mayo Clinic IRB. The authors declare no conflicts of interest. The authors have nothing to report.
No takes yet. Share an insight, caveat, or question.
Bhatt et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: